Mechanistically, SGLT2 inhibitors act predominantly through hemodynamic and cardiorenal pathways, whereas GLP-1 receptor agonists exert metabolic, anti-inflammatory, and anti-atherosclerotic effects, providing a rationale for potential complementarity
The product is free of unpleasant tastes and residual odors, and is suitable for supplementation of the athlete's diet
That is the central principle
Emerging clinical trials are exploring the efficacy of GLP-1 drugs in treating conditions such as: Cardiovascular Disease (CVD): Given the high prevalence of CVD in China, there is significant interest in using GLP-1 drugs to reduce cardiovascular risk in patients with obesity and diabetes
Hoeijmakers L, Lucassen PJ, Korosi A
when blood sugar drops, they stimulate glucagon secretion